دورية أكاديمية
أعرض في EDS

Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.

التفاصيل البيبلوغرافية
العنوان: Efficacy of Aflibercept as initial treatment for neovascular age-related macular degeneration in an Iraqi patient sample.
المؤلفون: Hussein ZR; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq., Omar SK; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq., Alkazraji RAM; Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq., Alsamarrai AN; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq., Alrubaye HS; Department of Ophthalmology, Ibn Al-Haithem Teaching Eye Hospital, Baghdad, Iraq., Al-Hussaniy HA; Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Iraq.; Dr. Hany Akeel Institute, Iraqi Medical Research Center, Baghdad, Iraq.; Department of Pharmacy, Bilad Alrafidain University College, Diyala, Iraq.
المصدر: Journal of medicine and life [J Med Life] 2023 Feb; Vol. 16 (2), pp. 235-243.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Carol Davila" University Press Country of Publication: Romania NLM ID: 101477617 Publication Model: Print Cited Medium: Internet ISSN: 1844-3117 (Electronic) Linking ISSN: 1844122X NLM ISO Abbreviation: J Med Life Subsets: MEDLINE
أسماء مطبوعة: Original Publication: Bucharest : "Carol Davila" University Press
مواضيع طبية MeSH: Angiogenesis Inhibitors*/therapeutic use , Wet Macular Degeneration*/diagnostic imaging , Wet Macular Degeneration*/drug therapy, Humans ; Treatment Outcome ; Follow-Up Studies ; Prospective Studies ; Iraq ; Vascular Endothelial Growth Factor A ; Visual Acuity ; Tomography, Optical Coherence ; Intravitreal Injections
مستخلص: Age-related macular degeneration (AMD) is a progressive degenerative eye disorder that primarily affects individuals over 50. It causes gradual loss of central vision and can lead to irreversible severe visual loss if left untreated. AMD is a leading cause of blindness in the developed world. This study aimed to investigate the effects of a loading dosage of intravitreal Aflibercept on functional and morphological responses in neovascular AMD, considering demographic characteristics and the link between AMD-related retinal symptoms at presentations. A prospective interventional study was conducted from November 2021 to September 2022 on a sample of Iraqi patients with neovascular AMD who had active choroidal neovascularization (CNV) lesions confirmed by OCT-A and received intravitreal Aflibercept 2mg injection as initial therapy (3 loading doses). Best-corrected visual acuity (BCVA) was used to measure functional responses, and central macular thickness (CMT) and maximum area of the retinal thickness (MART) (by SD-OCT) were used to measure morphological responses. The study included 48 patients (57 eyes) with active neovascular AMD. The mean difference of BCVA in log MAR (0.2 ± 0.7) significantly improved from 1.3±0.7 at baseline to 1.1±0.8 after loading Aflibercept (P=0.034). The mean difference in CMT 113.6 ± 125.9 was statistically significant (P<0.0001). Also, the mean change in MART significantly decreased from 444.2 ± 127.1 µm at baseline to 348.7±74.5 µm (p < 0.0001) after loading Aflibercept. This study demonstrated that Aflibercept is a functionally and anatomically successful treatment for neovascular AMD.
Competing Interests: The authors declare no conflict of interest.
(©2023 JOURNAL of MEDICINE and LIFE.)
References: Ophthalmology. 2014 Jan;121(1):193-201. (PMID: 24084500)
Ophthalmology. 2015 Apr;122(4):822-32. (PMID: 25578255)
BMC Ophthalmol. 2020 Aug 6;20(1):324. (PMID: 32762659)
Angiogenesis. 2012 Jun;15(2):171-85. (PMID: 22302382)
Ophthalmologe. 2010 Dec;107(12):1109-14. (PMID: 21153575)
Ophthalmol Retina. 2018 Jul;2(7):676-683. (PMID: 31047376)
BMC Ophthalmol. 2021 Aug 10;21(1):294. (PMID: 34376158)
Prog Retin Eye Res. 2001 Nov;20(6):705-32. (PMID: 11587915)
Invest Ophthalmol Vis Sci. 2011 Apr 25;52(5):2741-8. (PMID: 20538987)
Ophthalmology. 2014 Jun;121(6):1237-45. (PMID: 24684838)
Ophthalmology. 2013 Sep;120(9):1860-70. (PMID: 23642377)
Eye (Lond). 2016 Feb;30(2):270-86. (PMID: 26634711)
N Engl J Med. 2006 Oct 5;355(14):1419-31. (PMID: 17021318)
Ophthalmology. 2016 Jul;123(7):1521-9. (PMID: 27157149)
Ophthalmology. 2016 Oct;123(10):2213-24. (PMID: 27566855)
Prog Retin Eye Res. 2016 Jan;50:1-24. (PMID: 26307399)
Clin Genet. 2013 Aug;84(2):160-6. (PMID: 23713713)
Ophthalmology. 2014 May;121(5):1092-101. (PMID: 24461586)
Ophthalmology. 2012 Jul;119(7):1388-98. (PMID: 22555112)
Health Qual Life Outcomes. 2006 Dec 21;4:97. (PMID: 17184527)
Ophthalmology. 2013 Jan;120(1):122-9. (PMID: 23047002)
Ophthalmology. 2009 Jan;116(1):57-65.e5. (PMID: 19118696)
Invest Ophthalmol Vis Sci. 2008 Jul;49(7):3115-20. (PMID: 18408176)
Br J Ophthalmol. 2014 Dec;98(12):1629-35. (PMID: 25079064)
Adv Ther. 2013 Dec;30(12):1111-27. (PMID: 24310208)
Ophthalmology. 2020 May;127(5):616-636. (PMID: 31864668)
Ophthalmology. 2019 Feb;126(2):252-260. (PMID: 30189282)
Ophthalmology. 2011 Jun;118(6):1089-97. (PMID: 21640257)
Invest Ophthalmol Vis Sci. 2017 Feb 1;58(2):1337-1345. (PMID: 28241322)
Retina. 2010 Oct;30(9):1420-5. (PMID: 20543764)
Ophthalmology. 2012 Dec;119(12):2537-48. (PMID: 23084240)
Ophthalmology. 2017 Mar;124(3):e31-e32. (PMID: 28219517)
Drugs Today (Barc). 2012 May;48(5):317-29. (PMID: 22645720)
Prog Retin Eye Res. 2018 Jul;65:127-146. (PMID: 29305324)
Ophthalmology. 2013 Nov;120(11):2292-9. (PMID: 23642856)
Retina. 2015 Sep;35(9):1735-42. (PMID: 25923956)
Ophthalmology. 2016 Apr;123(4):865-75. (PMID: 26783095)
N Engl J Med. 2006 Oct 5;355(14):1432-44. (PMID: 17021319)
Graefes Arch Clin Exp Ophthalmol. 2020 Jul;258(7):1411-1417. (PMID: 32306096)
Acta Ophthalmol. 2018 Mar;96(2):120-133. (PMID: 29130626)
Expert Opin Pharmacother. 2012 Mar;13(4):585-91. (PMID: 22300011)
Ophthalmology. 2018 Jul;125(7):1037-1046. (PMID: 29454660)
Ophthalmology. 2011 May;118(5):831-9. (PMID: 21146229)
Cold Spring Harb Perspect Med. 2014 Oct 03;5(1):a017178. (PMID: 25280900)
Invest Ophthalmol Vis Sci. 2011 Mar 01;52(3):1599-605. (PMID: 21051733)
Neuron. 2012 Jul 12;75(1):26-39. (PMID: 22794258)
Asian Pac J Cancer Prev. 2022 Sep 01;23(9):3151-3156. (PMID: 36172678)
Photonics. 2018 Jun;5(2):. (PMID: 31321222)
Retina. 2015 May;35(5):975-81. (PMID: 25627086)
Ophthalmology. 2011 Jun;118(6):1098-106. (PMID: 21640258)
Ophthalmology. 2021 Mar;128(3):417-424. (PMID: 32781110)
Br J Ophthalmol. 2003 Mar;87(3):307-11. (PMID: 12598444)
Retina. 2019 Nov;39(11):2077-2083. (PMID: 30161093)
JAMA Ophthalmol. 2016 Feb;134(2):182-90. (PMID: 26661463)
Br J Ophthalmol. 2008 May;92(5):667-8. (PMID: 18356264)
فهرسة مساهمة: Keywords: Aflibercept; anti-VEGF; neovascular age-related macular degeneration (AMD); prospective study; vascular endothelial growth factor (VEGF)
المشرفين على المادة: 15C2VL427D (aflibercept)
0 (Angiogenesis Inhibitors)
0 (Vascular Endothelial Growth Factor A)
تواريخ الأحداث: Date Created: 20230320 Date Completed: 20230321 Latest Revision: 20230321
رمز التحديث: 20231215
مُعرف محوري في PubMed: PMC10015577
DOI: 10.25122/jml-2022-0356
PMID: 36937463
قاعدة البيانات: MEDLINE
الوصف
تدمد:1844-3117
DOI:10.25122/jml-2022-0356